Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, By Drug Class (Antidepressants, Hormone Therapy, Anticonvulsant, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2031.
Vasomotor Menopausal Symptoms (VMS) Treatment Market Analysis and Size
The market for vasomotor menopausal symptoms (VMS) treatment is driven by the increasing prevalence of menopausal symptoms among women worldwide. Hormone therapy, particularly estrogen therapy, remains a widely used and effective treatment for VMS, although concerns about its safety have led to an increased demand for alternative therapies. Non-hormonal treatments such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are gaining popularity due to their efficacy and safety profiles. The growing awareness about menopausal symptoms and their impact on quality of life is driving women to seek treatment, further fueling market growth.
The global vasomotor menopausal symptoms (VMS) treatment market size was valued at USD 17.75 billion in 2023 and is projected to reach USD 28.72 billion by 2031, with a CAGR of 6.20% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Antidepressants, Hormone Therapy, Anticonvulsant, and Others), Route of Administration (Oral, Parenteral, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
Zhejiang Huahai Pharmaceutical Co., Ltd (China), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc (U.S.), Hikma Pharmaceutical PLC (U.K.), Amneal Pharmaceuticals LLC. (U.S.), Alembic Pharmaceuticals Limited (India), Zydus Group (India), Dr. Reddy’s Laboratories Ltd (India), Abbvie, Inc (U.S.), Sun Pharmaceutical Industries Ltd (India), Apotex Inc (Canada), Aurobindo Pharma (India), Endo Pharmaceuticals plc (Ireland), Lupin (India), Novartis AG (Switzerland), WOCKHARDT (India)
|
|
Market Opportunities
|
|
Market Definition
Vasomotor Menopausal Symptoms (VMS), also known as hot flashes or night sweats, are common symptoms experienced by women during menopause. These symptoms are caused by hormonal changes, specifically the decline in estrogen levels, which can impact the body's ability to regulate temperature. VMS treatment aims to alleviate these symptoms and improve the quality of life for women experiencing them. Treatment options include hormone therapy (estrogen therapy), which can effectively reduce the frequency and severity of VMS, and non-hormonal treatments such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and lifestyle changes.
Vasomotor Menopausal Symptoms (VMS) Treatment Market Dynamics
Drivers
- Increasing Aging Population
With women living longer, the number of women experiencing menopause and its associated symptoms, including VMS, is expected to rise. As women age, the decline in estrogen levels leads to symptoms such as hot flashes and night sweats. This demographic trend creates a growing demand for effective VMS treatment options, driving market growth.
- Technological Advancements in Treatment Options
Ongoing technological advancements include the development of new drug formulations and delivery methods that offer more effective and convenient treatment options for women experiencing VMS. Transdermal patches and gels, offer a non-oral method for hormone therapy, providing women with a variety of options for managing their symptoms. In addition, novel drug formulations and delivery methods aim to improve treatment efficacy and patient compliance, further boosting market growth.
Opportunities
- Rising Awareness and Treatment-seeking Behavior
Women are becoming more informed about the impact of VMS on their quality of life and are actively seeking effective treatment options to manage these symptoms. This is supported by a growing body of information available through various channels, including healthcare providers, online resources, and community outreach programs. With growing awareness, an increasing number of women are expected to seek treatment for VMS, thereby expanding the market for VMS treatment options.
- Development of Novel Treatment Options
The development of novel treatment options for Vasomotor Menopausal Symptoms (VMS), such as new drug formulations and non-hormonal therapies, has the potential to meet market demands by providing women experiencing VMS with more effective and safer options. For instance, new drug formulations may provide improved symptom relief with fewer side effects, while non-hormonal therapies offer alternatives for women who cannot or prefer not to use hormone-based treatments. These advancements in treatment options are likely to drive market expansion as they provide more choices for patients and healthcare providers.
Restraints/Challenges
- Safety Concerns Associated with Hormone Therapy
Safety concerns regarding the long-term use of hormone therapy, particularly the risk of cardiovascular events and cancer, have led to a decline in the use of hormone therapy and an increased demand for alternative treatments. Healthcare providers and patients are increasingly cautious about the risks associated with hormone therapy, leading to a shift towards non-hormonal treatment options. As a result, market growth for hormone therapy products is being impacted by these safety concerns.
- Availability of Non-pharmacological Alternatives
The availability of non-pharmacological alternatives, such as lifestyle modifications and alternative therapies, is often preferred by women seeking natural or holistic approaches to managing VMS, as they may perceive them to be safer or more in line with their personal beliefs and values. Non-pharmacological alternatives include dietary changes, exercise, stress management techniques, and acupuncture, among others. The availability and acceptance of these alternatives by women experiencing VMS contribute to the limited growth of the pharmacological treatment market, as some women may choose these options over traditional medication.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Vasomotor menopausal symptoms (VMS) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In April 2024, Knight Therapeutics Inc. announced the launch of Imvexxy and Bijuva in Canada. Imvexxy is indicated for the treatment of postmenopausal moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA). It is the only product in its therapeutic class to offer 4 mcg and 10 mcg doses. BIJUVA is the first Health Canada-approved combination of 1 mg of estradiol and 100 mg of micronized progesterone in a single daily oral capsule. It is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause in women with an intact uterus
- In May 2023, Astellas Pharma Inc.'s VEOZAH (fezolinetant) became the first nonhormonal neurokinin 3 (NK3) receptor antagonist to receive FDA approval. VEOZAH is indicated for the treatment of vasomotor symptoms (VMS) associated with menopause.
- In March 2022, Amyris, Inc. acquired MenoLabs, LLC, a company specializing in treating menopausal symptoms and conducting research in this field. Through this acquisition, Amyris, Inc. expanded its portfolio of menopausal treatment products.
Vasomotor Menopausal Symptoms (VMS) Treatment Market Scope
The market is segmented on the basis of drug class, route of administration, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- Antidepressants
- Fluoxetine
- Paroxetine
- Sertraline
- Hormone Therapy
- Anticonvulsant
- Phenytoin
- Phenobarbital
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Vasomotor Menopausal Symptoms (VMS) Treatment Market Regional Analysis/Insights
The market is analyzed and market size insights and trends are provided by country, drug class, route of administration, end-users, and distribution channel as referenced above.
The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.
North America is expected to dominate the market due to its advanced and comprehensive healthcare infrastructure. The region boasts well-established healthcare facilities and services, ensuring widespread access to medical automation technologies. Moreover, North America exhibits high levels of consumer awareness regarding healthcare advancements, leading to a more receptive market for medical automation solutions. The presence of key market players and ongoing technological innovations further solidify the market growth in the region.
Asia-Pacific is expected to witness significant growth during the forecast period due to a growing patient pool, increasing investments in the healthcare sector, and rising government support. Traditional Chinese medicine is highly instrumental in managing menopausal symptoms and accelerating menopause treatment market growth. Women have an array of choices for controlling menopausal symptoms because of the coexistence of modern therapeutic approaches and traditional Japanese medicine, such as Kampo therapy. These factors intensify the adoption of menopause treatments in Japan.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for vasomotor menopausal symptoms (VMS) treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Vasomotor Menopausal Symptoms (VMS) Treatment Market Share Analysis
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are:
- Zhejiang Huahai Pharmaceutical Co., Ltd (China)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Pfizer Inc (U.S.)
- Hikma Pharmaceutical PLC (U.K)
- Amneal Pharmaceuticals LLC. (U.S.)
- Alembic Pharmaceuticals Limited (India)
- Zydus Group (India)
- Dr. Reddy’s Laboratories Ltd (India)
- Abbvie, Inc (U.S.)
- Sun Pharmaceutical Industries Ltd (India)
- Apotex Inc (Canada)
- Aurobindo Pharma (India)
- Endo Pharmaceuticals plc (Ireland)
- Lupin (India)
- Novartis AG (Switzerland)
- WOCKHARDT (India)
SKU-